Updated on: Jan 9 2014

Brief Summary EMN-02


The EMN-02 is titled:

"A randomized phase III study to compare Bortezomib, Melphalan, Prednisone (VMP) high dose Melphalan followed by Bortezomib, Lenalidomide, Dexamethasone (VRD) consolidation and Lenalidomide maintenance in patients with newly diagnosed multiple myeloma" and is

  • comparing Bortezomib, Melphalan, Prednisone (VMP) with High Dose Melphalan followed autologous stem cell transplantation (ASCT); 
  • comparing Bortezomib, Lenalidomide, Dexamethasone(VRD) as consolidation versus no consolidation and 
  •  comparing single versus tandem high dose Melphalan with ASCT.

The patient population is patients with symptomatic multiple myeloma who are previously untreated in ISS stages 1-3 between the age 18-65 years inclusive.


The study design is prospective, multicenter, intergroup, randomized with an expected duration of induction, stem cell collection and intensification of 6 - 9 months.


Consolidation with VRD will last 2 months.


Maintenance therapy with Lenalidomide will be given until relapse and all patients will be followed until 10 years after registration.


Further study details can be seen here - provided by Stichting Hemato-Oncologie voor Volwassenen Nederland. 

Secr. Hans E. Johnsen | Depart. of Haematology | Aalborg University Hospital | Sdr. Skovvej 15 | DK-9000 Aalborg | Denmark | T:+45 9766 3871 | F:+45 9766 6369